Cargando…
Quantifying mortality burden in patients with cancer due to COVID‐19 in the US: A national cross‐sectional analysis
INTRODUCTION: There is limited information on the impact of certain social factors on mortality outcomes in patients with cancer and COVID‐19 on a national scale. This study aims to characterize excess mortality and analyze a subset of sociodemographic trends in COVID‐19 and cancer mortality. METHOD...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501232/ https://www.ncbi.nlm.nih.gov/pubmed/37537960 http://dx.doi.org/10.1002/cam4.6364 |
_version_ | 1785106076037808128 |
---|---|
author | Jambunathan, Bhaghyasree Lang, Jacob Mays, Malik Ekwenna, Obi |
author_facet | Jambunathan, Bhaghyasree Lang, Jacob Mays, Malik Ekwenna, Obi |
author_sort | Jambunathan, Bhaghyasree |
collection | PubMed |
description | INTRODUCTION: There is limited information on the impact of certain social factors on mortality outcomes in patients with cancer and COVID‐19 on a national scale. This study aims to characterize excess mortality and analyze a subset of sociodemographic trends in COVID‐19 and cancer mortality. METHODS: Patients with cancer listed on their death certificates from 2018 to 2021 and patients with COVID‐19 and cancer listed on multiple cause of death certificates from the CDC Wide‐Ranging Online Data for Epidemiologic Research database from March 2020 to December 2021 were included. Age‐adjusted mortality rates (AAMR) per 1,000,000 population were compared across race/ethnicity groups, sex, and census regions. Crude mortality rates were compared across different age groups and regions based on urbanization status. RESULTS: Average AAMR in patients with COVID‐19 and cancer was 41.7 in 2020 and 56.7 in 2021. CONCLUSIONS: Mortality rates in patients with cancer and COVID‐19 were significantly higher in certain populations. Targeted interventions are necessary to improve outcomes. |
format | Online Article Text |
id | pubmed-10501232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105012322023-09-15 Quantifying mortality burden in patients with cancer due to COVID‐19 in the US: A national cross‐sectional analysis Jambunathan, Bhaghyasree Lang, Jacob Mays, Malik Ekwenna, Obi Cancer Med BRIEF COMMUNICATION INTRODUCTION: There is limited information on the impact of certain social factors on mortality outcomes in patients with cancer and COVID‐19 on a national scale. This study aims to characterize excess mortality and analyze a subset of sociodemographic trends in COVID‐19 and cancer mortality. METHODS: Patients with cancer listed on their death certificates from 2018 to 2021 and patients with COVID‐19 and cancer listed on multiple cause of death certificates from the CDC Wide‐Ranging Online Data for Epidemiologic Research database from March 2020 to December 2021 were included. Age‐adjusted mortality rates (AAMR) per 1,000,000 population were compared across race/ethnicity groups, sex, and census regions. Crude mortality rates were compared across different age groups and regions based on urbanization status. RESULTS: Average AAMR in patients with COVID‐19 and cancer was 41.7 in 2020 and 56.7 in 2021. CONCLUSIONS: Mortality rates in patients with cancer and COVID‐19 were significantly higher in certain populations. Targeted interventions are necessary to improve outcomes. John Wiley and Sons Inc. 2023-08-03 /pmc/articles/PMC10501232/ /pubmed/37537960 http://dx.doi.org/10.1002/cam4.6364 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | BRIEF COMMUNICATION Jambunathan, Bhaghyasree Lang, Jacob Mays, Malik Ekwenna, Obi Quantifying mortality burden in patients with cancer due to COVID‐19 in the US: A national cross‐sectional analysis |
title | Quantifying mortality burden in patients with cancer due to COVID‐19 in the US: A national cross‐sectional analysis |
title_full | Quantifying mortality burden in patients with cancer due to COVID‐19 in the US: A national cross‐sectional analysis |
title_fullStr | Quantifying mortality burden in patients with cancer due to COVID‐19 in the US: A national cross‐sectional analysis |
title_full_unstemmed | Quantifying mortality burden in patients with cancer due to COVID‐19 in the US: A national cross‐sectional analysis |
title_short | Quantifying mortality burden in patients with cancer due to COVID‐19 in the US: A national cross‐sectional analysis |
title_sort | quantifying mortality burden in patients with cancer due to covid‐19 in the us: a national cross‐sectional analysis |
topic | BRIEF COMMUNICATION |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501232/ https://www.ncbi.nlm.nih.gov/pubmed/37537960 http://dx.doi.org/10.1002/cam4.6364 |
work_keys_str_mv | AT jambunathanbhaghyasree quantifyingmortalityburdeninpatientswithcancerduetocovid19intheusanationalcrosssectionalanalysis AT langjacob quantifyingmortalityburdeninpatientswithcancerduetocovid19intheusanationalcrosssectionalanalysis AT maysmalik quantifyingmortalityburdeninpatientswithcancerduetocovid19intheusanationalcrosssectionalanalysis AT ekwennaobi quantifyingmortalityburdeninpatientswithcancerduetocovid19intheusanationalcrosssectionalanalysis |